Momordicine-I, another bioactive metabolite of Momordica charantia, has been investigated in the setting of head and neck cancer cells (JHU022, JHU029, Cal27), demonstrating inhibitory potential in cell viability in a dose-dependent manner, with an IC50 value of 10.4 μg/mL, while also inhibiting c-Met and its downstream signaling molecules c-Myc, survivin, and cyclin D1 through the inactivation of STAT3 [33]. The gene discussed is MYC; the disease is head and neck cancer.